Lupin received USFDA approval for generic Pitolisant Tablets, strengthening its US portfolio and specialty generics presence. Shares remain technically weak despite strong long-term returns, with FIIs raising their stake while mutual fund holdings declined. The stock trades below most key moving averages, keeping near-term momentum subdued despite the positive regulatory development.
Source :- Markets-Economic Times Read More
